Q3 was in line and the robust performance in Speciality Care, particularly Dupixent, and Emerging Markets was offset by a dismal show in Vaccines and Consumer Healthcare. While Dupixent and China should continue to be the key growth drivers in the mid-term, we anticipate a recovery in Vaccines and Consumer Healthcare in the coming quarters. However, Oncology is still a question mark. We eagerly wait the new CEO’s first capital markets day in December 2019.
07 Nov 2019
Dupixent continued to run the show in Q3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Dupixent continued to run the show in Q3
Sanofi (SANO:WBO) | 0 0 1.3% | Mkt Cap: 81,283m
- Published:
07 Nov 2019 -
Author:
Rishabh Kochar -
Pages:
4
Q3 was in line and the robust performance in Speciality Care, particularly Dupixent, and Emerging Markets was offset by a dismal show in Vaccines and Consumer Healthcare. While Dupixent and China should continue to be the key growth drivers in the mid-term, we anticipate a recovery in Vaccines and Consumer Healthcare in the coming quarters. However, Oncology is still a question mark. We eagerly wait the new CEO’s first capital markets day in December 2019.